The combined entity will retain the Jasper Therapeutics name and continue trading on the Nasdaq under the ticker JSPR. Under the terms of the deal, Kira shareholders will control just under 50% of the new company, while private placement investors take a 43% stake. Jasper’s original shareholders retain a 6.7% interest, though they are also eligible for $30 million in contingent value rights tied to the regulatory approval of the briquilimab treatment by 2029.
In section Market Quotes
Jasper Therapeutics Absorbs Kira Pharmaceuticals in Stock Merger
Jasper Therapeutics has finalized an all-stock merger with Kira Pharmaceuticals, a deal aimed at consolidating drug pipelines while securing a $132 million capital injection. The move triggered a sharp market reaction, sending Jasper shares climbing 63% in after-hours trading as investors reacted to the new ownership structure.
CEO Jeet Mahal remains at the helm, citing Kira’s specialized complement portfolio as a primary driver for the acquisition. Beyond the merger, Kira concurrently out-licensed two drug candidates to Mirador Therapeutics, securing an immediate $12 million payment plus future development milestones. The $132 million raised through the sale of preferred stock is intended to provide the company with sufficient operating runway through the second half of 2028.
Comments (0)
No comments yet. Be the first!